M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials
Chiara Cerrato,Roman Hájek,Francesco Di Raimondo,Tommaso Caravita,Antonietta Falcone,Francesca Patriarca,Stefano Pulini,Paola Finsinger,Giovannino Ciccone,Paolo Corradini,Agostina Siniscalchi,Francesca De' Donato,Dina Ben Yehuda,Massimo Offidani,Jiri Minarik,Roberto Ria,Federica Cavallo,Lucio Catalano,Maide Cavalli,Ludek Pour,Maria Teresa Petrucci,Izhar Hardan,Mario Boccadoro,Andrew Spencer,Antonio Palumbo +24 more
TL;DR: In NDMM patients, Mel200-ASCT significantly improved PFS and OS in comparison with CC+R, and these data suggest intensifying treatment in good-prognosis patients and in patients with a chemo-sensitive disease.
Journal ArticleDOI
Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG)
Roman Hájek,Evangelos Terpos,Hans C. Lee,Ajai Chari,Caitlin Costello,Noemi Puig,Xavier Leleu,Jesus G. Berdeja,Faith E. Davies,Katja Weisel,Saad Z. Usmani,Vania Hungria,Mario Boccadoro,Robert M. Rifkin,Jeffrey A. Zonder,Gordon Cook,Lucie Brožová,Magda Bařinová,Kaili Ren,Roxanne Cacioppo,Tomas Skacel,Dawn Marie Stull,Vladimir Maisnar +22 more
Journal ArticleDOI
Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial
Valeria Magarotto,Maria Teresa Petrucci,Francesco Di Raimondo,Luděk Pour,Tommaso Caravita,Vlastimil Scudla,Anna Maria Cafro,Anna Marina Liberati,Stefano Spada,Maisnar Vladimir,Norbert Pescosta,Roberto Ria,Massimo Offidani,Sara Bringhen,Annalisa Bernardini,Francesca Patriarca,Paolo Corradini,Roberto Foa,Nicola Cascavilla,Lucio Catalano,Andrew Spencer,Roman Hájek,Mario Boccadoro,Antonio Palumbo +23 more
TL;DR: MEL200 significantly prolonged PFS and OS compared with CRD, regardless of maintenance, and lenalidomide treatment was comparable in the 2 groups, in an open-label, randomized, phase 3 study of newly diagnosed, transplant-eligible myeloma patients.
Journal ArticleDOI
Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Marco Cerrano,Elena Crisà,Patrizia Pregno,Chiara Aguzzi,Paola Riccomagno,Mario Boccadoro,Dario Ferrero +6 more
TL;DR: The strategy could be as effective as front line second generation TKI, with most of patients still receiving imatinib, a drug of better known long‐term side effects and lower cost.
Journal ArticleDOI
S872 carfilzomib lenalidomide dexamethasone (krd) with or without transplantation in newly diagnosed myeloma (forte trial): efficacy according to risk status
Chiara Cerrato,D. Rota Scalabrini,Angelo Belotti,Monica Galli,Elena Zamagni,Massimo Offidani,Paola Omedè,Francesco Monaco,Patrizia Tosi,Ombretta Annibali,Francesco Pisani,Rossella Troia,Anna Pascarella,Felicetto Ferrara,Michele Cea,B. Dalla Palma,Francesca Patriarca,Sara Aquino,Angelo D. Palmas,A. Siniscalchi,Mariella Grasso,Antonio Palumbo,Antonio Ledda,Pellegrino Musto,Michele Cavo,Mario Boccadoro +25 more